Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19
Joshua D. Geleris, Yifei Sun, Jonathan Platt, et al.
New England Journal of Medicine (2020) Vol. 382, Iss. 25, pp. 2411-2418
Open Access | Times Cited: 1662

Showing 26-50 of 1662 citing articles:

Risk Factors for Hospitalization, Mechanical Ventilation, or Death Among 10 131 US Veterans With SARS-CoV-2 Infection
George N. Ioannou, Emily R. Locke, Pamela Green, et al.
JAMA Network Open (2020) Vol. 3, Iss. 9, pp. e2022310-e2022310
Open Access | Times Cited: 364
COVID-19 and kidney transplantation: Results from the TANGO International Transplant Consortium
Paolo Cravedi, Suraj Sarvode Mothi, Yorg Azzi, et al.
American Journal of Transplantation (2020) Vol. 20, Iss. 11, pp. 3140-3148
Open Access | Times Cited: 356
Discriminating mild from critical COVID-19 by innate and adaptive immune single-cell profiling of bronchoalveolar lavages
Els Wauters, Pierre Van Mol, Abhishek D. Garg, et al.
Cell Research (2021) Vol. 31, Iss. 3, pp. 272-290
Open Access | Times Cited: 321
Emerging treatment strategies for COVID-19 infection
Maria Gavriatopoulou, Ioannis Ntanasis‐Stathopoulos, Eleni Korompoki, et al.
Clinical and Experimental Medicine (2020) Vol. 21, Iss. 2, pp. 167-179
Open Access | Times Cited: 316
Calcium channel blocker amlodipine besylate therapy is associated with reduced case fatality rate of COVID-19 patients with hypertension
Leike Zhang, Yuan Sun, Hao‐Long Zeng, et al.
Cell Discovery (2020) Vol. 6, Iss. 1
Open Access | Times Cited: 301
Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis
Thibault Fiolet, Anthony Guihur, Mathieu E. Rebeaud, et al.
Clinical Microbiology and Infection (2020) Vol. 27, Iss. 1, pp. 19-27
Open Access | Times Cited: 295
Lung transplantation for patients with severe COVID-19
Ankit Bharat, Melissa Querrey, Nikolay S. Markov, et al.
Science Translational Medicine (2020) Vol. 12, Iss. 574
Open Access | Times Cited: 295
In situ detection of SARS-CoV-2 in lungs and airways of patients with COVID-19
Inga‐Marie Schaefer, Robert F. Padera, Isaac H. Solomon, et al.
Modern Pathology (2020) Vol. 33, Iss. 11, pp. 2104-2114
Open Access | Times Cited: 290
Hydroxychloroquine for Early Treatment of Adults With Mild Coronavirus Disease 2019: A Randomized, Controlled Trial
Natàlia Casamitjana, Marc Corbacho-Monné, María Ubals, et al.
Clinical Infectious Diseases (2020) Vol. 73, Iss. 11, pp. e4073-e4081
Open Access | Times Cited: 278
Pharmaco-Immunomodulatory Therapy in COVID-19
John G. Rizk, Kamyar Kalantar‐Zadeh, Mandeep R. Mehra, et al.
Drugs (2020) Vol. 80, Iss. 13, pp. 1267-1292
Open Access | Times Cited: 275
COVID-19: A review of therapeutic strategies and vaccine candidates
Vladislav Izda, Matlock A. Jeffries, Amr H. Sawalha
Clinical Immunology (2020) Vol. 222, pp. 108634-108634
Open Access | Times Cited: 272
Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials
Cathrine Axfors, Andreas M. Schmitt, Perrine Janiaud, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 272
COVID-19 in patients with lung cancer
Jie Luo, Hira Rizvi, Isabel R. Preeshagul, et al.
Annals of Oncology (2020) Vol. 31, Iss. 10, pp. 1386-1396
Open Access | Times Cited: 255
Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis
Jean‐Christophe Lagier, Matthieu Million, Philippe Gautret, et al.
Travel Medicine and Infectious Disease (2020) Vol. 36, pp. 101791-101791
Open Access | Times Cited: 254
Patients with COVID-19: in the dark-NETs of neutrophils
Maximilian Ackermann, Hans‐Joachim Anders, Rostyslav Bilyy, et al.
Cell Death and Differentiation (2021) Vol. 28, Iss. 11, pp. 3125-3139
Open Access | Times Cited: 252
Epidemiology, pathogenesis, clinical presentations, diagnosis and treatment of COVID-19: a review of current evidence
Sayeeda Rahman, Maria Teresa Villagomez Montero, Kherie Rowe, et al.
Expert Review of Clinical Pharmacology (2021) Vol. 14, Iss. 5, pp. 601-621
Open Access | Times Cited: 250
Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial
Peter Horby, Marion Mafham, Louise Linsell, et al.
medRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 239
The immunology of COVID-19: is immune modulation an option for treatment?
Jixin Zhong, Jungen Tang, Cong Ye, et al.
The Lancet Rheumatology (2020) Vol. 2, Iss. 7, pp. e428-e436
Open Access | Times Cited: 237
Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study
Nicolas Hoertel, Marina Sánchez‐Rico, Raphaël Vernet, et al.
Molecular Psychiatry (2021) Vol. 26, Iss. 9, pp. 5199-5212
Open Access | Times Cited: 234
Azithromycin in the treatment of COVID-19: a review
Daniel Echeverría-Esnal, Clara Martín‐Ontiyuelo, María Eugenia Navarrete-Rouco, et al.
Expert Review of Anti-infective Therapy (2020) Vol. 19, Iss. 2, pp. 147-163
Open Access | Times Cited: 233
Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 In Vitro and SARS-CoV In Vivo
Stuart Weston, Christopher M. Coleman, Robert Haupt, et al.
Journal of Virology (2020) Vol. 94, Iss. 21
Open Access | Times Cited: 227
Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19
Adrían V. Hernández, Yuani M. Roman, Vinay Pasupuleti, et al.
Annals of Internal Medicine (2020) Vol. 173, Iss. 4, pp. 287-296
Closed Access | Times Cited: 220
Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity
Lore Vanderbeke, Pierre Van Mol, Yannick Van Herck, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 217
Open science saves lives: lessons from the COVID-19 pandemic
Lonni Besançon, Nathan Peiffer‐Smadja, Corentin Ségalas, et al.
BMC Medical Research Methodology (2021) Vol. 21, Iss. 1
Open Access | Times Cited: 216
Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2
Mohammad Mehdi Ghahremanpour, Julian Tirado‐Rives, M.G. Deshmukh, et al.
ACS Medicinal Chemistry Letters (2020) Vol. 11, Iss. 12, pp. 2526-2533
Open Access | Times Cited: 208

Scroll to top